AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30929571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic retinal vessel analysis (DVA) measuring maximum arteriolar dilation (aMax) and venular dilation (vMax).
Number of subjects: 214
Study 30929678 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 22.5-mg depot
Number of subjects: 163
Study 30929749 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO 2015 guidelines for treatment eligibility
Number of subjects: 1190
Study 30929749 — intervention group
Group type: COMPARATOR
Intervention: EASL 2017 guidelines for treatment eligibility
Number of subjects: 1190
Study 30929841 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 392
Study 30929841 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-based chemotherapy
Number of subjects: 392
Study 30929841 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-gemcitabine
Number of subjects: 392
Study 30930133 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular Insulin (RI) on TPN
Number of subjects: 161
Study 30930133 — intervention group
Group type: COMPARATOR
Intervention: Glargine Insulin (GI)
Number of subjects: 161
Study 30931323 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Vecchietti's operation
Number of subjects: 15
Study 30931323 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 15
Study 30931426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 15
Study 30931695 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 85
Study 30931695 — intervention group
Group type: COMPARATOR
Intervention: Fuji IX GP Extra
Number of subjects: 85
Study 30931695 — intervention group
Group type: COMPARATOR
Intervention: Fuji II LC
Number of subjects: 85
Study 30931726 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB angioplasty in CLI patients
Number of subjects: 156
Study 30931726 — intervention group
Group type: COMPARATOR
Intervention: DCB angioplasty in IC patients
Number of subjects: 156
Study 30931746 — intervention group
Group type: EXPERIMENTAL
Intervention: TAMP bioactive glass scaffolds
Number of subjects: 6
Study 30931746 — intervention group
Group type: COMPARATOR
Intervention: Control (left empty)
Number of subjects: 6
Study 30932132 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants meeting the protein recommendation (0.8 g/kg/d)
Number of subjects: 11680
Study 30932132 — intervention group
Group type: COMPARATOR
Intervention: Participants not meeting the protein recommendation (0.8 g/kg/d)
Number of subjects: 11680
Study 30932132 — intervention group
Group type: COMPARATOR
Intervention: Participants aged over 70 years not meeting the protein recommendation
Number of subjects: 11680
Study 30932170 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg)
Number of subjects: 240
Study 30932170 — intervention group
Group type: COMPARATOR
Intervention: Control (no granisetron)
Number of subjects: 240
Study 30932287 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIMix
Number of subjects: 82
Study 30932287 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical MRI
Number of subjects: 82
Study 30933618 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I testing
Number of subjects: 0
Study 30933618 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30935383 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment with radical prostatectomy, limited duration systemic therapy for a total of six months (leuprolide, abiraterone acetate with prednisone, and apalutamide), metastasis-directed stereotactic body radiotherapy (SBRT), and post-operative fractionated radiotherapy if pT ≥ 3a, N1, or positive margins are present.
Number of subjects: 0
Study 30935391 — intervention group
Group type: EXPERIMENTAL
Intervention: C4Ma3
Number of subjects: 984
Study 30935391 — intervention group
Group type: EXPERIMENTAL
Intervention: C4Ma3 multiplied by fibrinogen
Number of subjects: 984
Study 30935391 — intervention group
Group type: COMPARATOR
Intervention: Fibrinogen
Number of subjects: 984
Study 30935397 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 33
Study 30935397 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study 30935734 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 400
Study 30935734 — intervention group
Group type: COMPARATOR
Intervention: Immunomodulators
Number of subjects: 400
Study 30935734 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNFα therapy
Number of subjects: 400
Study 30935734 — intervention group
Group type: COMPARATOR
Intervention: Colectomy
Number of subjects: 400
Study 30935734 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline clinical severity, high baseline haemoglobin, week 4 clinical remission
Number of subjects: 400
Study 30935734 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial peptide gene signature
Number of subjects: 400
Study 30935734 — intervention group
Group type: EXPERIMENTAL
Intervention: Abundance of Ruminococcaceae
Number of subjects: 400
Study 30935734 — intervention group
Group type: EXPERIMENTAL
Intervention: Abundance of Sutterella
Number of subjects: 400
Study 30936057 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP) plus interleukin-2
Number of subjects: 0
Study 30936057 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30936738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 0
Study 30936738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab plus NSAID (naproxen, celecoxib, or diclofenac)
Number of subjects: 0
Study 30936738 — intervention group
Group type: COMPARATOR
Intervention: Active comparator (naproxen, celecoxib, diclofenac, or oxycodone)
Number of subjects: 0
Study 30936738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30936738 — intervention group
Group type: COMPARATOR
Intervention: Active comparator
Number of subjects: 0
Study 30936830 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of Ticagrelor, dosage not specified, duration not specified
Number of subjects: 0
Study 30937138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) drops containing tree pollen allergens (ORALVAC) with a rapid home-based up-dosing schedule
Number of subjects: 164
Study 30937138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) drops containing tree pollen allergens (ORALVAC)
Number of subjects: 164
Study 30937138 — intervention group
Group type: COMPARATOR
Intervention: Pre-seasonal treatment initiation with SLIT
Number of subjects: 164
Study 30937138 — intervention group
Group type: COMPARATOR
Intervention: Control group (previously established schedules of SLIT)
Number of subjects: 164
Study 30937156 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (three small-group sessions over 6 months)
Number of subjects: 23
Study 30937156 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study 30937345 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic product (Lactoflorene)
Number of subjects: 0
Study 30937394 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 1064
Study 30937394 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 1064
Study 30937421 — intervention group
Group type: EXPERIMENTAL
Intervention: SHINE intervention promoting early initiation (EI) and exclusive breastfeeding (EBF) delivered by village health workers.
Number of subjects: 0
Study 30937580 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (highest tertile)
Number of subjects: 3049
Study 30937580 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (highest tertile)
Number of subjects: 3049
Study 30937580 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA + EPA (highest tertile)
Number of subjects: 3049
Study 30937580 — intervention group
Group type: EXPERIMENTAL
Intervention: Total n-3 PUFAs (highest tertile)
Number of subjects: 3049
Study 30937889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 0
Study 30937899 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for MC3R C17A + G241A haplotype
Number of subjects: 237
Study 30937899 — intervention group
Group type: COMPARATOR
Intervention: Heterozygous and wild-type participants
Number of subjects: 237
Study 30938420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac phenotype (n'=210)
Number of subjects: 1411
Study 30938420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac mutations or ATTRwt
Number of subjects: 1411
Study 30938626 — intervention group
Group type: EXPERIMENTAL
Intervention: Early DISH criteria
Number of subjects: 3634
Study 30938626 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater reliability
Number of subjects: 3634
Study 30938626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarater reliability
Number of subjects: 3634
Study 30938645 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (tonic water)
Number of subjects: 323
Study 30938645 — intervention group
Group type: EXPERIMENTAL
Intervention: SDF solution
Number of subjects: 323
Study 30938645 — intervention group
Group type: EXPERIMENTAL
Intervention: SDF solution followed by potassium iodide (KI) solution
Number of subjects: 323
Study 30938687 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Coaching (HC) with 8 sessions over a 5-month period
Number of subjects: 0
Study 30938687 — intervention group
Group type: COMPARATOR
Intervention: Usual care (including education about DD)
Number of subjects: 0
Study 30938687 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 0
Study 30938688 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response and Text Message (IVR-T) intervention including automated text messages or phone calls in English or Spanish, reminders for appointments, medication refills, and motivational messages; offered home blood pressure monitor.
Number of subjects: 295
Study 30938688 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 295
Study 30938714 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning chemotherapy followed by CD19-targeted CAR T-cells (19-28z).
Number of subjects: 20
Study 30938714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib therapy at the time of autologous T-cell collection and/or CAR T-cell administration.
Number of subjects: 20
Study 30938714 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning chemotherapy and 19-28z CAR T-cells.
Number of subjects: 20
Study 30938796 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid PET
Number of subjects: 16008
Study 30938874 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital heart disease (CHD)
Number of subjects: 0
Study 30938874 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 0
Study 30938874 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms, self-esteem level, and types of treatment received
Number of subjects: 0
Study 30938874 — intervention group
Group type: COMPARATOR
Intervention: Healthy counterparts (control group)
Number of subjects: 0
Study 30939086 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis-based group intervention combining self-care and hypnosis; details on dosage and duration not available.
Number of subjects: 0
Study 30939136 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (RIF)
Number of subjects: 15
Study 30939136 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 15
Study 30939136 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (LZD)
Number of subjects: 15
Study 30939136 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MFX)
Number of subjects: 15
Study 30939136 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine (CFZ)
Number of subjects: 15
Study 30939136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA)
Number of subjects: 15
Study 30939136 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanamycin (KAN)
Number of subjects: 15
Study 30939290 — intervention group
Group type: EXPERIMENTAL
Intervention: Latinos
Number of subjects: 402
Study 30939290 — intervention group
Group type: COMPARATOR
Intervention: Non-Latino Whites (NLWs)
Number of subjects: 402
Study 30939488 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia group (defined by sex-specific TPMT/height cutoff)
Number of subjects: 186
Study 30939488 — intervention group
Group type: COMPARATOR
Intervention: Nonsarcopenia group (defined by sex-specific TPMT/height cutoff)
Number of subjects: 186
Study 30939488 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia group
Number of subjects: 186
Study 30939489 — intervention group
Group type: EXPERIMENTAL
Intervention: EBR 50 mg plus GZR 50 mg once daily for 12 weeks
Number of subjects: 30
Study 30939489 — intervention group
Group type: COMPARATOR
Intervention: EBR 50 mg plus GZR 100 mg once daily for 12 weeks (control group)
Number of subjects: 30
Study 30939908 — intervention group
Group type: EXPERIMENTAL
Intervention: WATCHMAN left atrial appendage occlusion device
Number of subjects: 1020
Study 30940123 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine TB examination (clinical evaluation, sputum smear microscopy, chest radiography)
Number of subjects: 360
Study 30940149 — intervention group
Group type: EXPERIMENTAL
Intervention: Option B+
Number of subjects: 50
Study 30940206 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook intervention posts tailored to readiness to quit smoking (N=180) in the Ready group.
Number of subjects: 29
Study 30940206 — intervention group
Group type: COMPARATOR
Intervention: Facebook intervention posts tailored to readiness to quit smoking (N=180) in the Not Ready group.
Number of subjects: 29
Study 30940206 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall STAND intervention rating.
Number of subjects: 29
Study 30940215 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised meal
Number of subjects: 22
Study 30940762 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour intervention (Sit-Less and Move-More stages) over 22 weeks (15-week intervention + 7-week follow-up) with individual coaching and a Fitbit for monitoring activity.
Number of subjects: 40
Study 30940770 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (0.5 mg/kg for 7 days)
Number of subjects: 44
Study 30940999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine
Number of subjects: 672
Study 30941094 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine, dosage and duration not available
Number of subjects: 0
Study 30941094 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30941095 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) intramuscular injections
Number of subjects: 0
Study 30941307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib and Cetuximab
Number of subjects: 0
Study 30941340 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous light-active physical activity at work
Number of subjects: 0
Study 30941702 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical specialties (SS)
Number of subjects: 190
Study 30941702 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical specialties (NSS)
Number of subjects: 190
Study 30942111 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug adherence assessment via toxicological urine analysis
Number of subjects: 18
Study 30942111 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated urine analysis over a time range of up to 17 months
Number of subjects: 18
Study 30942111 — intervention group
Group type: EXPERIMENTAL
Intervention: Single time point urine analysis
Number of subjects: 18
Study 30942148 — intervention group
Group type: EXPERIMENTAL
Intervention: Contegra 12 mm
Number of subjects: 53
Study 30942148 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary homograft
Number of subjects: 53
Study 30942698 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile EMA tool with auditory alerts (3 alerts at 10-min intervals)
Number of subjects: 59
Study 30942698 — intervention group
Group type: COMPARATOR
Intervention: Mobile EMA tool without auditory alerts
Number of subjects: 59
Study 30942881 — intervention group
Group type: EXPERIMENTAL
Intervention: TFV-DP <800 fmol/punch
Number of subjects: 451
Study 30942881 — intervention group
Group type: EXPERIMENTAL
Intervention: TFV-DP 800 to <1650 fmol/punch
Number of subjects: 451
Study 30942881 — intervention group
Group type: EXPERIMENTAL
Intervention: TFV-DP <800 fmol/punch (virologically suppressed)
Number of subjects: 451
Study 30942881 — intervention group
Group type: EXPERIMENTAL
Intervention: TFV-DP 800 to <1650 fmol/punch (virologically suppressed)
Number of subjects: 451
Study 30943079 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR group
Number of subjects: 156
Study 30943079 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 156
Study 30943079 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-legged drop jump
Number of subjects: 156
Study 30943079 — intervention group
Group type: EXPERIMENTAL
Intervention: CoD tests
Number of subjects: 156
Study 30943079 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-legged hop for distance
Number of subjects: 156
Study 30943123 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) at 12.0 Gy/fraction (fx)
Number of subjects: 120
Study 30943123 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) at 11.5 Gy/fx
Number of subjects: 120
Study 30943123 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) at 12.0 Gy/fx
Number of subjects: 120
Study 30943124 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable toxicity, or physician or patient decision.
Number of subjects: 98
Study 30943769 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontan patients
Number of subjects: 10
Study 30943769 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 10
Study 30943782 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of shoes equipped with the foot compression device (Footbeat™, AVEX, Grand Junction, CO, USA) for 4 weeks
Number of subjects: 0
Study 30943843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening intervention
Number of subjects: 0
Study 30943843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study 30943913 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum klotho levels in patients with metabolic syndrome (MS)
Number of subjects: 1754
Study 30943913 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum klotho levels
Number of subjects: 1754
Study 30943913 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum klotho levels < 518 pg/mL
Number of subjects: 1754
Study 30943928 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor cell (CTC) detection before therapy and after one course of preoperative FOLFOX
Number of subjects: 36
Study 30943928 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CTC detection
Number of subjects: 36
Study 30943979 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 522
Study 30943979 — intervention group
Group type: COMPARATOR
Intervention: Conventional risk factors and other markers (high-sensitivity C-reactive protein, pulse wave analysis, heart rate variability)
Number of subjects: 522
Study 30943998 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 59
Study 30944020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 30944020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 30944020 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) chemo monotherapy regimens (cetuximab, docetaxel, or methotrexate)
Number of subjects: 0
Study 30944151 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised 3D-engineered stents
Number of subjects: 10
Study 30944585 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 1461
Study 30944736 — intervention group
Group type: EXPERIMENTAL
Intervention: High engagement with messaging
Number of subjects: 201
Study 30944736 — intervention group
Group type: COMPARATOR
Intervention: Self-tracking
Number of subjects: 201
Study 30944763 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy with D2 lymph node dissection (LND)
Number of subjects: 157
Study 30945522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from Aegean and Mediterranean regions
Number of subjects: 819
Study 30945522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from Black Sea, Southeast, and East Anatolia regions
Number of subjects: 819
Study 30945522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from Mediterranean and Southeast Anatolia regions
Number of subjects: 819
Study 30945522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from Southeast Anatolia
Number of subjects: 819
Study 30945522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from Mediterranean, Southeast Anatolia, and Black Sea regions
Number of subjects: 819
Study 30945522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from East Anatolia
Number of subjects: 819
Study 30945522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from Black Sea region
Number of subjects: 819
Study 30945607 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30945636 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartWare centrifugal-flow ventricular assist device (HVAD) implantation via thoracotomy approach
Number of subjects: 144